CRB and Inveready back Amadix

Life sciences investor CRB committed €1.5m through CRB Bio II, which held a first close on €30m in 2012. Inveready provided the remaining capital.

As part of the deal, Amadix has merged with Inveready portfolio company Transbiomed in a share swap.

Inveready backed Transbiomed in 2011, in a $1.2m funding round that included the Department of Science and Innovation as well as ACC1Ó, an agency set up by the Catalan government to support Catalan enterprises.

Company
Amadix was founded in 2010 as a spinout from clinical stage biotech firm TCD Pharma, backed by Ade Gestion Sodical, CRB Inverbio, Real de Vellón and Seguranza. The firm develops diagnostic tools to address medical needs in oncology. Early products addressed medical needs in the treatment of lung and colon cancer.

Amadix's shareholding structure now includes CRB Inverbio, Inveready, Seguranza Technology Fund, ADE Capital Sodical and the company's founders.

The expanded company will now include Transbiomed, which span out of Vall d'Hebrón Research Institute in 2007. The firm has developed an appliance for the detection of prostate cancer.

People
Josep Maria Echarri is CEO of Inveready and worked on the transaction. Enrique Castellón is president of CRB Bio II.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Expansion
• Healthcare
• Spain
• Inveready First Capital
• Cross Road Biotech